Date: 2016-07-18
Type of information: Licensing agreement
Compound: pritumumab
Company: Nascent Biotech (USA - CA) Zhejiang Hisun Pharmaceuticals (China)
Therapeutic area: Cancer - Oncology
Type agreement: licensing - development - commercialisation
Action mechanism:
- monoclonal antibody. Pritumumab is a fully natural human antibody that was derived using proprietary technology from a B-cell isolated from a tumor draining lymph node of a patient with cervical cancer. The recognized target is ecto-domain vimentin that is expressed on the cell surface of a variety of adenocarcinomas, including brain cancers and melanoma, but not expressed by normal tissues and cells.
Disease: epithelial cancers (which include brain, pancreas, colon, lung and breast)
Details:
- • On July 18, 2016, Nascent Biotech and Zhejiang Hisun Pharmaceutical announced they have entered into an exclusive licensing agreement for the development and commercialization of Nascent’s primary asset, pritumumab, a monoclonal antibody for the treatment of epithelial cancers (which include brain, pancreas, colon, lung and breast), in mainland China. The agreement between the two companies licenses development, manufacture and commercialization rights for Pritumumab to Hisun, for the treatment of epithelial cancers in China. Under the terms of the agreement, Nascent Biotech will provide to Hisun its Master Cell Bank and related technology, which will allow Hisun to quickly begin manufacturing and further clinical development of Pritumumab in China.
Financial terms:
Latest news:
Is general: Yes
